Ascletis Pharma Inc. provided earnings guidance for the year ended December 31, 2021. For the year, The company expects to record a turnaround from a gross loss to a gross profit for the year ended December 31, 2021 and record a gross profit ranging from approximately RMB 38.5 million to RMB 40.1 million, representing an increase of approximately 264% to 270%. The Group expects to record a revenue ranging from approximately RMB 76.1 million to RMB 77.6 million for the year ended December 31, 2021, representing an increase of approximately 117% to 122%, as compared with a revenue of approximately RMB 35.0 million for the corresponding year ended December 31, 2020.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.8 HKD | -3.61% |
|
-11.11% | -45.21% |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-45.21% | 104M | |
+2.99% | 95.18B | |
-4.34% | 37.55B | |
-10.41% | 33.75B | |
+75.79% | 28.2B | |
-14.61% | 15.63B | |
-3.46% | 13.63B | |
-12.31% | 11.5B | |
+184.77% | 10.81B | |
-54.13% | 9.23B |
- Stock Market
- Equities
- 1672 Stock
- News Ascletis Pharma Inc.
- Ascletis Pharma Inc. Provides Earnings Guidance for the Year Ended December 31, 2021